炎症在肺纤维化发病机制中的作用:机制与治疗启示
纤维化性间质性肺病(fILD)包括一组异质性间质性肺病,可能由系统性疾病或环境暴露引起的持续炎症所致。特发性肺纤维化为典型fILD,以进展性纤维化、炎症有限和高死亡率为特征;其他fILD的纤维化与炎症贡献不一,且仅部分由基础诊断决定。炎症与纤维化并非离散序贯事件,而是动态交织的过程,其相互作用因病因不同而异。
要点
- 炎症与纤维化是动态交织而非序贯事件,相互作用因病因不同而异。
- 炎症既可作为纤维化重塑的驱动因素和后果,也参与纤维化消退与控制。
- 纤维化与炎症信号通路显著重叠,理解驱动纤维化的病理机制对优化个体化治疗至关重要。
核心结论
- 炎症与纤维化并非离散序贯事件,而是动态交织的过程,其性质与相对重要性因基础病因不同而异。
- 炎症既可作为纤维化重塑的驱动因素和后果,形成自我维持的前馈环路,也参与纤维化消退与控制。
- 纤维化与炎症信号通路显著重叠,其相互作用是疾病起始与进展的核心。
- 阐明细胞对不同损伤刺激应答的调控机制,为优化患者分层和个体化治疗提供机会。
研究设计与样本
- 本文为综述,结合实验性肺纤维化模型与转化研究进展,回顾当前治疗进展与未来方向。
主要发现
- 纤维化性间质性肺病(fILD)包括一组异质性间质性肺病,可能由系统性疾病或环境暴露引起的持续炎症所致。
- 特发性肺纤维化为典型fILD,以进展性纤维化、炎症有限和高死亡率为特征。
- 其他fILD的纤维化与炎症贡献不一,且仅部分由基础诊断决定,多数fILD中可观察到广泛的疾病表型谱。
临床怎么用
- 以纤维化为主与以炎症为主的间质性肺病治疗策略差异显著,需基于病理机制优化个体化治疗。
- 理解驱动纤维化的病理机制有助于细化患者分层并量身定制治疗以改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibrotic interstitial lung diseases (fILDs) encompass a heterogeneous group of interstitial lung diseases and may arise from persistent inflammation caused by systemic disease or environmental exposures. Idiopathic pulmonary fibrosis, the prototypical fILD, is characterised by progressive fibrosis, limited inflammation, and a high mortality rate. In contrast, other fILDs display variable contributions of fibrosis and inflammation that are only partially determined by the underlying diagnosis. Within most fILDs, a broad spectrum of disease phenotypes can be observed.Inflammation and fibrosis are not discrete, sequential events, but rather dynamically intertwined processes. The nature and relative importance of these interactions vary according to the underlying aetiology. Inflammation can function as both a driver and a consequence of fibrotic remodelling, establishing self-perpetuating feed-forward loops, yet also playing a role in fibrosis resolution and control. As therapeutic strategies for predominantly fibrotic versus inflammatory interstitial lung diseases differ substantially, improved understanding of the pathomechanisms that drive fibrosis is essential for optimising personalised treatment approaches.Fibrotic and inflammatory signalling pathways show considerable overlap, and their interaction is central to disease initiation and progression. Elucidating the mechanisms that govern cellular responses to diverse injurious stimuli provides an opportunity to refine patient stratification and tailor therapies to improve outcomes. Insights from experimental models of pulmonary fibrosis and translational research have significantly advanced our understanding of these processes and are reviewed in this article, together with current therapeutic advances and future directions.
引用
- Nazemi N, Crestani B, Helou DG, et al. The role of inflammation in the pathogenesis of pulmonary fibrosis: mechanisms and treatment implications. Eur Respir J. 2026. PMID: 42660607. doi:10.1183/13993003.00258-2026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。